Invivyd (IVVD) Net Cash Flow Growth (1y) (2022 - 2025)
Invivyd (IVVD) Net Cash Flow Growth (1y) (2022 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 53.46% |
| 10 | Invivyd | 105.10 Mn | -121.59 Mn | 16.07 Mn | 477.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 477.64% |
| Sep 30, 2025 | 222.07% |
| Jun 30, 2025 | 68.24% |
| Mar 31, 2025 | -88.95% |
| Dec 31, 2024 | -299.42% |
| Sep 30, 2024 | -168.50% |
| Jun 30, 2024 | -817.08% |
| Mar 31, 2024 | -132.72% |
| Dec 31, 2023 | 110.11% |
| Sep 30, 2023 | 130.43% |
| Jun 30, 2023 | 92.11% |
| Mar 31, 2023 | 443.83% |
| Dec 31, 2022 | -390.95% |
| Sep 30, 2022 | -329.40% |
| Jun 30, 2022 | -119.03% |
| Mar 31, 2022 | 57.86% |